Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Genfit Secures Medicare Coverage in the US for its NashNext Test

Genfit announced on July 2nd the acquisition of Medicare coverage for NASHnext, its non-invasive diagnostic test for metabolic steatohepatitis (MASH). This US decision opens up reimbursement access for patients identified as at risk.


Genfit Secures Medicare Coverage in the US for its NashNext Test

Medicare Coverage Acquired for NASHnext

Genfit has secured Medicare coverage for NASHnext, its non-invasive diagnostic tool designed to identify patients suffering from or at risk of MASH. This recognition by the US federal health insurance program signifies administrative acceptance of the test based on the group's NIS4 technology.

NASHnext was launched in June in partnership with Labcorp through its OnDemand platform, thus broadening patient access to early detection of this metabolic liver disease.

Expansion of Reimbursement Considered with Other Insurers

Beyond Medicare coverage, Genfit indicates plans to seek further reimbursement from other health insurance schemes in the United States. This trajectory reflects the typical timeline for market access in the American market.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36,4 millions d'euros
  • Quarterly revenue: 36,4 millions d'euros
  • Revenue growth: -7,1 %
Guidance from the release
  • « conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
  • Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
  • Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
  • Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
  • Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
  • Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
  • Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours